Novel therapeutics for Hodgkin's lymphoma

---

Editorial

Author Details : Sunil Chaudhry*, Abhijit Trailokya, Manoj Naik

Volume : 7, Issue : 1, Year : 2024

Article Page : 1-5

https://doi.org/10.18231/j.sajhp.2024.001

Suggest article by email

Get Permission

---

Abstract

( Hodgkins LymphomaHL) was first described by Thomas Hodgkin in 1832., is a malignant disorder, a rare B cell lymphoma (mutant lymphocytes) with reasonable outcome due to the fair cure rates achieved by modern chemotherapy and/or radiotherapy. The incidence of HL is 2.6 cases per 100,000 people, accounts for 10% lymphoma cases. The Epstein–Barr virus (EBV) is detected in nearly 45% of HL patients Most of the affected patients are between ages 20 to 40 years. HL is uncommon in children < 5>

Keywords: Hodgkin lymphoma, PD-1 inhibitor, Antibody-drug conjugate, Brentuximab, Immunotherapy, PET-adapted therapy, Allogeneic stem cell transplant

How to cite : Chaudhry S, Trailokya A, Naik M, Novel therapeutics for Hodgkin's lymphoma. South Asian J Health Prof 2024;7(1):1-5

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.